

CytoSorbents Corporation

OTCBB: CTSO

An Emerging Leader in
Critical Care Immunotherapy

Fiscal Year 2013 Review – March 31, 2014



Safe Harbor Statement

Statements in this presentation regarding CytoSorbents Corporation and its operating subsidiary CytoSorbents, Inc that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. It is routine for our internal projections and expectations to change. Although these expectations may change, we are under no obligation to inform you if they do. Actual events or results may differ materially from those contained in the projections or forward-looking statements. The following factors, among others, could cause our actual results to differ materially from those described in a forward-looking statement: our history of losses; potential fluctuations in our quarterly and annual results; competition, inability to achieve regulatory approval for our device, technology systems beyond our control and technology-related defects that could affect the companies' products or reputation; risks related to adverse business conditions; our dependence on key employees; competition for qualified personnel; the possible unavailability of financing as and if needed; and risks related to protecting our intellectual property rights or potential infringement of the intellectual property rights of third parties. This list is intended to identify only certain of the principal factors that could cause actual results to differ from those discussed in the forward-looking statements. Readers are referred to a discussion of important risk factors detailed in the Company's Form 10-K filed with the Securities and Exchange Commission on March 31, 2014 and other reports and documents filed from time to time by us, which are available online at www.sec.gov.

Conference Call Participants

Dr. Phillip Chan, MD, PhD

Chief Executive Officer and President

Vincent Capponi, MS

Chief Operating Officer

Kathleen Bloch, MBA, CPA

Chief Financial Officer

Dr. Christian Steiner, MD

Vice President of Sales and Marketing

Christopher Cramer, MS, MBA

Vice President of Business Development

Moderator: Donna Marincas – CytoSorbents Corporation

CytoSorbents is an Emerging Leader in Critical Care Immunotherapy



Leading the Prevention or Treatment of
Life-Threatening Inflammation in the ICU



CytoSorbents

Working to Save Lives Through Blood Purification

Immunotherapy: A \$100+ Billion Market

Immune Suppression
Infection
Cancer
Poor healing

Allergy/Asthma/Anaphylaxis
Autoimmune
Sepsis/SIRS
Organ Failure

LOW

NORMAL IMMUNE RESPONSE


HIGH

Activate the Immune Response

- **Vaccines (\$30B+ revenue)**
 - Sanofi, Merck, GSK, Pfizer, Novartis
- **Cancer Immunotherapy (\$20B+ revenue)**
 - Rituxan, Herceptin, Erbitux, others
 - Provenge, Yervoy

Suppress the Immune Response

- **Antihistamines/Steroids (\$20B+ revenue)**
 - Zyrtec, Claritin, Allegra, Advair, Singulair
- **Autoimmune Diseases (\$30B+ revenue)**
 - Enbrel, Humira, Remicade, others
- **Critical Care Immunotherapy (\$20B+ est)**



- Approved in the EU
- Available in 9 countries
- Generating Revenue
- 30+ post market studies
- 100+ KOLs
- Little to no competition




CytoSorbents

Working to Save Lives Through Blood Purification


What is the \$20B Critical Care Opportunity?

Millions of people are admitted to the intensive care unit in hospitals in the U.S. and the European Union each year with deadly inflammatory conditions

Sepsis



ARDS



Burn Injury




Trauma



Pancreatitis



Influenza



Surgical



- In these conditions, little exists to reduce the inflammation and actively help patients get better. Rather, patients often need to be kept alive with machines called “life support”, with the hope that their bodies heal on their own over time
- Without “active” therapies, patients linger at a cost of \$2,000-3,000 a day* with a risk of death of 1 in every 3 patients
- The US alone spends nearly 1% of its GDP or ~\$80-90 billion on critical care**


* Cooper, L, et al, Crit Care Med 2004, 32(11):2247-2253.

** Halpern, NA, et al., Crit Care Med 2010, 38(1):65-71.



Cytokines Fuel the Fire of Inflammation

- Cytokines are small proteins that normally help stimulate and regulate the immune system and control inflammation
- Cytokines are a dual edged sword
 - They are required for proper immune system function
 - However, in mild to moderate excess, cytokines can cause or exacerbate disease (e.g. autoimmune diseases)
- But cytokines in vast excess, called “cytokine storm” can lead to a massive uncontrolled systemic inflammatory response syndrome (SIRS) leading to multiple organ dysfunction syndrome (MODS) or multiple organ failure (MOF)



Massive Inflammation Causes Organ Failure

Organ failure occurs when vital organs stop working, causing nearly half of all deaths in the ICU.



Little can be done to prevent or treat it today



CytoSorbents

Working to Save Lives Through Blood Purification


CytoSorb® Removes the Fuel to the Fire

- CytoSorb® represents a powerful immunotherapy to control inflammation
- Approved in the European Union as the only specifically approved cytokine filter
- Clinically proven to reduce key cytokines in blood by 30-50% in critically ill patients
- Approved for use in any situation where cytokines are elevated
- Safe: More than 1,500 human treatments, no severe device related adverse events



The Heart of the Technology

The underlying blood purification technology is based on state-of-the-art biocompatible, highly porous polymer beads that act like tiny sponges to remove harmful substances from blood




Each bead is about the size of a grain of salt




- Protected by 32 issued US patents and multiple applications pending
- Manufactured at our ISO 13485 certified facility in New Jersey
- One of the highest grade medical sorbents on the medical market today

Goal: To Prevent or Treat Organ Failure




Improve
Patient
Outcome
and
Survival




Decrease
Costs Of
ICU and
Patient
Care

Sepsis



ARDS



Burn Injury




Trauma



Pancreatitis



Influenza



Surgical



The Potential to Revolutionize Critical Care Medicine



CytoSorbents

Working to Save Lives Through Blood Purification

\$15+ Million in US Government Support

- DARPA awarded \$3.8M five year (2012) contract as part of “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins
- U.S. Army awarded \$1.15M SBIR contracts for trauma and burn injury research (2011-13)
- U.S. Air Force is funding a 30 patient human pilot study in trauma valued at \$3M (2013). FDA approved trial to begin this year
- US Dept of Health and Human Services awarded \$0.5M grant (2010) for therapies that can save lives and reduce costs under the QTDP Program
- NIH grant awarded \$7M five year (2006-2010) to University of Pittsburgh and Dr. John Kellum to research CytoSorb bead for treatment of sepsis
- NIH/NHLBI awarded \$0.2M Phase I SBIR to advance the HemoDefend purification technology intended to improve the quality and safety of blood transfusions (2013)



2013 Operating and Financial Highlights



CytoSorb® An Excellent Business Model

- **Huge market**

CytoSorb® is sold to hospitals and critical care physicians, targeting a “need to have” \$20 billion worldwide critical care opportunity addressing organ failure

- **Little to no competition**

- **Critical care physicians understand the problem**

- **It is a plug and play high margin disposable “razorblade”**

Hospital’s existing hemodialysis infrastructure is the “razor”, no new hardware

- **Technicians already know how to use the device**

- **CytoSorb® is reimbursed in Germany/Austria at >\$500/cartridge.**

Depending on the application and devices used, revenue potential per patient ~\$1-5K

- **Affordable yet profitable with gross margins of 60%+, target > 80%**

- **Intensive care units are highly centralized easy for a small sales force to access**




2013 Revenue Results


	2013	2012	% Incr.
Product revenue	\$ 821,787	\$ 151,574	442%
Grant income	1,600,880	1,191,362	34%
Total revenue	\$ 2,422,667	\$ 1,342,936	80%

- 2013 was the first full year of CytoSorb® commercialization
- Achieved total 2013 revenue of ~\$2.4 million, including product and grant income
- 2013 CytoSorb® sales were ~\$822,000 versus \$152,000 in 2012
- Q4 2013 CytoSorb® invoiced orders were ~\$351,000. Due to common carrier delays, ~\$37,000 in orders were picked up on January 2, 2014, resulting in recognized revenue for Q4 2013 of ~\$314,000, a 54% increase over Q3 2013
- 2014 grant revenue was ~\$1.6M, compared to ~\$1.2M in 2013

Continued Strong Product Growth Since Launch



Record CytoSorb Sales Expected for Q1 2014



Expecting Q1 2014 CytoSorb sales between \$530-\$570K

Direct Sales: Germany, Austria, Switzerland

We are currently working with 100+ KOLs in the largest and most important university and public hospitals in most major cities in Germany and many in Austria and the UK

Partial List:

- University of Aachen
- University of Bonn
- Helios Berlin Buch
- Charite Mitte and Charite Virchow
- Helios Erfurt
- University of Goettingen
- University of Greifswald
- University of Hamburg - Eppendorf
- University of Jena
- University of Kiel
- University of Leipzig
- Trauma Hospital of Linz
- European Medical University of Oldenburg
- University of Rostock
- University of Ulm
- Medical University of Vienna
- Vienna General Hospital (AKH)



Addressable market in Germany alone: \$1.0-1.5B




E.U. Approval Opens Global Distribution

Signed UK, Ireland, Netherlands, Turkey, Russia and India. Expanding to other parts of Europe and other countries outside the EU that accept the CE Mark



Product Sales (TTM)




Have now exceeded milestone of >\$1M TTM CytoSorb® sales

Strong Gross Margins

- Overall 2013 product gross margins exceeded 60%
- Sales prices have remained constant
- Gross margins will vary based on the ratio of direct sales vs. sales to distributors, but are expected to remain very healthy
- Higher scale production is expected to result in lower product costs and improve our gross margin percentage
- As CytoSorb[®] sales increase, gross margin on our products will help generate working capital

Working Capital



Multiple Sources of Capital to Fund Growth

- March 11, 2014 receipt of \$9,451,000 from our preregistered offering has fortified our balance sheet.
- Increasing Product Sales – high gross margins and increasing sales will drive us closer to cash flow breakeven
- Continue to receive grant funding from DARPA, SBIR, etc.
- Potential strategic partnerships

Investing in Growth: Catalysts for 2014



#1: Core Focus on **CytoSorb**[®] Sales



100+ Key Opinion Leaders In Germany and Austria



Increase Sales Team + Clinical and Distributor support



Reference Hospitals with Expansion to MICU, SICU, CICU, Trauma ICU



Driving Departmental Adoption targeting Junior and Senior Physicians



30+ Post-Market Studies Generate Clinical Data in Many Applications



Orders from Existing Distributors. Further International Expansion and Reimbursement Focus

Sales Infrastructure Targets For 2014

2013		
Direct Sales	Distributors	Partners
Germany Austria Switzerland	5 Distributors (UK, Ireland, Netherlands, Turkey, Russia)	Biocon (India)
4 sales reps		
Clinical Support (1)		
US Manufacturing + QA/QC Staff		
Reimbursement		


Targets for 2014		
Direct Sales	Distributors	Partners
Germany Austria Switzerland	10+ Distributors	2+ Partners
10 sales reps	Distributor/Partner Support Rep	
Clinical Support Staff (2)		
Support increases in sales with increases in US Manufacturing + QA/QC Staff		
Reimbursement Support		



“Market Pull” from Key Applications

Sepsis

Afflicts 2.5 million people in the US and EU annually without an approved therapy, representing a \$6-8 billion market





- ↓ Inflammatory cytokines (organ failure)
- ↓ Immunosuppressive cytokines (infection)
- ↓ Many bacterial toxins (organ failure)
- 🎯 Directs immune system where to go and where not to go (organ failure)

No other single therapy has demonstrated this broad range of activity

Cardiac Surgery

Use of CytoSorb either during or after cardiac surgery to prevent organ dysfunction and organ failure is a \$500M – 1B total addressable market in the US and EU alone



CytoSorbents

Working to Save Lives Through Blood Purification


Targeting Significant Revenue Acceleration

\$M: 2014 Sales

~\$822K
2013 Sales



Revenue Multiplying Effect



* Number of cartridges used only to graphically demonstrate the multiplier effect concept. This does not reflect revenue guidance for 2014.



DIVI 2013 First Ever CytoSorb Users Meeting

Great energy and excitement from actual CytoSorb users in Germany and Austria



- Treatment pioneers from all over Germany and Austria gathered to share their clinical experiences using CytoSorb
- Because of the strong interest amongst CV surgeons, there was a dedicated track on cardiac surgery
- Hospital of the University of Jena Hospital announced development of CytoSorb Registry



DIVI 2013 CytoSorbents Sponsored Symposium



More than 120 people from Germany/Austria attended in Leipzig, Germany



ISICEM 2014 CytoSorbents Symposium



CytoSorbents

We booked a seat for you...

SIRS and SEPSIS
New therapeutic approach with CytoSorb®

CytoSorbents Symposium, ISICEM, Brussels 2014
Wednesday March 19th, 6:15pm - 7:45pm, Room: The AHC


- Overshooting the inflammatory response – The Root of all evil?
Herwig Gerlach, Berlin, Germany
- Blood purification in SIRS and Sepsis: A new paradigm
John Aklonis, Pittsburgh, USA
- Clinical experience: Severe Sepsis/Septic Shock and CytoSorb® Therapy
Michael Quenert, Oettingen, Germany
- Clinical experience: Post-Cardio-Pulmonary-Bypass-SIRS and CytoSorb® Therapy
Karl Stage, Lein, Germany

Flying Dinner


CytoSorbents Europe GmbH
Strobelstraße 12A
10117 Berlin, Germany Tel. +49 30 693 99 140
Fax: +49 30 693 99 149
support@cytosorbents.com



#2: Expand Clinical Trial Capability and Data



U.S. Cardiac Surgery Pivotal Trial



Rationale for U.S. Cardiac Surgery Trial

The path to approval of CytoSorb® in the U.S. is potentially faster, less expensive and less risky than seeking approval for critical care applications such as sepsis

- Seeing significant “market pull” for this application. 20+ heart centers in Germany and Austria. Data coming in Q2-Q3 2014 from cardiac surgery trials
- Very large markets: 500K cardiac surgeries in the U.S., 500K in the E.U., more than 1.5 million in the world each year - a potential total addressable market of \$1 billion or more
- CytoSorb is the only cytokine reduction technology capable of direct installment in a bypass circuit into a heart lung machine without the need for another machine
- CytoSorb could completely displace leukoreduction filters used in the heart-lung machine circuit, an existing multi-million dollar market, while significantly expanding the market.
- Trial is more straightforward, less expensive and less risky. Patients are much more homogenous and can be enrolled quickly, treatment and follow-up is relatively short.
- Endpoint would NOT be mortality, but a clinical endpoint such as incidence of respiratory failure or acute kidney injury
- Once approved in the U.S., can expand U.S. applications through a label extension strategy while driving usage in cardiac surgery outside of the U.S. where it is already approved

U.S. Cardiac Surgery Pivotal Trial

Two potential paths to U.S. regulatory approval for CytoSorb in cardiac surgery. Expect to submit IDE during Summer 2014

1) Intra-Operative Usage of CytoSorb to Prevent Post-operative Complications


- Multi-center randomized controlled trial
- Enrich for cardiac surgery patients at high risk for inflammation and hemolysis and treat DURING surgery with CytoSorb in a bypass circuit
- Primary endpoint: Reduction in post-operative complications (AKI vs ALI/ARDS)

OR

2) Post-Operative Usage of CytoSorb to Treat Post-operative SIRS

- Multi-center randomized controlled trial
- CytoSorb is used AFTER surgery to treat patients who develop SIRS
- Primary endpoint: Relative reduction in incidence of organ dysfunction

Germany “Pivotal” Sepsis Trial



Treatment Alternatives Continue to Shrink

Sepsis:

- Early Goal Directed Therapy: Early optimization of hemodynamics and oxygenation in septic shock patients failed to demonstrate improvement in 60-day mortality (21.0% vs 18.2% control) versus usual care in large 1,341 patient U.S. multi-center trial. This reverses the findings of a landmark 2001 study
- Endotoxin removal with Toraymyxin in patients with peritonitis due to organ perforation with septic shock (ABDO-MIX Trial) showed no mortality benefit vs standard of care therapy in a 243-patient randomized controlled multi-center trial in France (preliminary data as presented at ISICEM 2014).

**CytoSorb remains one of the few promising therapies
in sepsis and other applications**

Goal: Increase the Odds of Success

- CytoSorb is one of the only therapies being used to treat sepsis today in Europe and elsewhere, and holds great promise in early studies.
- The European Sepsis Trial and Dosing Study demonstrate that up to 24 hours of treatment is safe. In these patients with advanced sepsis and multiple organ failure, those with cytokine storm or those \geq age 65 may have the best benefit
- In actual clinical practice, there have also been many remarkable treatment successes in patients with either severe sepsis or septic shock, particularly when used early
- Our goal is to ensure our pivotal sepsis study design has the best chance of success. The many sepsis studies with CytoSorb® that are being conducted, including the Dosing study, will help us get there
- When ready, we plan to conduct this study in Germany, led by our major collaborators in the SepNet Trials Network

#3: Our Bead Technology Enables a Diverse and Valuable Pipeline




Critical Care, High Risk Surgery




Blood Collection & Transfusion

ContrastSorb



CT Imaging, Interventional Radiology

DrugSorb



Drug Overdose, Chemo Removal

BetaSorb



Improving Dialysis

CE Mark Approved


Under Development



CytoSorbents

Working to Save Lives Through Blood Purification

Potential for Strategic Partnerships*




*Companies listed here are used simply as examples of companies in these respective verticals. We make no other representations to our relationship with any of these companies.



Biocon Strategic Partnership: The Most Comprehensive Treatment for Sepsis



Treat the Primary Infection



Treat the Massive
Inflammatory Response

Ms. Kiran Shaw, Chairman and Managing Director of Biocon, India's largest biotechnology company – Jan 2014 Q3 2014 earnings report: “Our recent launches of Alzumab and CytoSorb® have done extremely well, with strong uptake by both doctors and patients.”



CytoSorbents

Working to Save Lives Through Blood Purification

2014 and **HemoDefend**[™]

Two major trials are expected to be reported in 2014 that may be very important to the HemoDefend platform

RECESS (Red Cell Storage Duration Study):

- New Blood (≤ 10 days) vs Old Blood (≥ 21 days) in 1,696 cardiac surgery patients
- Primary endpoint: Change in multiple organ dysfunction score (MODS) from pre-surgery

ABLE (Age of Blood Evaluation Study):

- New Blood (≤ 10 days) vs Standard Issue Blood (~15-20 days) in 2,510 critically-ill patients
- Primary endpoint: 90-day all-cause mortality
- HemoDefend is designed to help keep new blood fresh and is supported by a Phase I SBIR grant from the National Heart, Lung, and Blood Institute (NHLBI)
- It removes contaminants from transfused blood products that accumulate during blood storage as blood gets old that can cause transfusion reactions and adverse events such as organ failure and death.
- We continue to advance development of HemoDefend towards commercialization increasing its value while de-risking the asset, with the goal of out-licensing



#4: Uplisting Targeted for 2H 2014

Increased institutional ownership and liquidity
the goal of uplisting to NYSE or NASDAQ



- Targeting major operational momentum into 2H 2014
 - Revenue Growth with increase in direct and distributor sales
 - Fixed strategy on US Pivotal trial in cardiac surgery and/or EU sepsis trial
 - Data in many applications from many post-market EU studies
 - Potential for strategic partnerships and monetization of pipeline
 - New product development
- Have already met with NYSE and NASDAQ
- Preparing company for uplisting
- Cultivating relationships with analysts and institutional investors


#5: CytoSorb is Being Used in a Broad Range of Applications



Case Report: Septic shock



57 year old male was diagnosed with gangrenous appendicitis

- Deterioration of clinical course due to severe respiratory failure requiring mechanical ventilation due to suspected pneumonia and aspiration
- Transferred to the ICU with septic shock requiring high doses of norepinephrine, aggressive IV hydration and antibiotics, acute respiratory distress syndrome, severe lactic acidosis, and low urine output
- Began CytoSorb therapy with immediate improvement in hemodynamic stability
 - Weaned off of all vasopressors by Day 2
 - Weaned off of mechanical ventilation by Day 5
 - Did not require dialysis therapy
 - Transferred out of the ICU to the step down unit by Day 9.






Case Report: Intra-op Cardiac Surgery

- 49 year old man developed a graft infection and sepsis, days after aortic arch replacement cardiac surgery
- Underwent a re-do operation with CytoSorb in a bypass circuit of the heart-lung machine
- Patient was expected to be highly unstable but instead was completely stable during the operation which was credited to the use of CytoSorb
- Patient went on to a full recovery, and left the hospital after a total of 12 days, without complications



Case Report: Post-op Cardiac Surgery

- 83 year old man underwent quadruple bypass but on Day 8 post-op, he developed pneumonia with septic shock, respiratory and renal failure
- The infection was polymicrobial with bacteremia
- Treated with CytoSorb and antibiotics
- Patient recovered and was discharged from the ICU by Day 7 to a respiratory weaning unit




Case Report: Severe Burn Injury

Patient in his mid-20's suffered severe burn injury with >60% total body surface area and also had severe smoke inhalation injury

- Baux (Burn injury severity) Score of 103 predicted mortality of 45-50%
- Patient was admitted to the ICU after developing shock requiring high doses of vasopressors, lung failure, and kidney injury
- CytoSorb was used continuously with renal support over 8 days, changing the cartridge each day
- Patient was weaned from vasopressors within 4 days
- Significant improvement in kidney and lung function
- Wound healing was much faster than expected
- Patient currently has a good prognosis for recovery

Case Report: Trauma & Rhabdomyolysis

- 25 year old high speed motor vehicle accident victim admitted with severe polytrauma including hemorrhagic shock requiring massive transfusion, head trauma, a broken leg, chest wall injuries, and others
- He was admitted to the neurosurgical ICU and underwent surgery to reduce intracranial pressure
- Developed severe rhabdomyolysis from muscle breakdown with myoglobin > 250,000 ng/mL and CK > 50,000 U/L
- CytoSorb + CRRT rapidly reduced myoglobin and restored kidney function (CRRT by itself does not remove myoglobin effectively). CytoSorb was changed daily




Case Report: Tylenol Overdose

A patient overdosed on 30 grams of Tylenol (> 12 g considered to have a very high risk of death due to liver failure and other complications)

- The patient subsequently developed multi-organ failure, with failure of the lungs, kidneys and liver, with collapse of the circulatory system
- Patient was at high risk for bleeding events
- Was stabilized within 24 hours of treatment with CytoSorb and survived

Case Report: Transport Stabilization

CytoSorb was used with ECMO to stabilize a 58 year old man for transport from Kuwait to a Berlin ICU after a massive heart attack



Flight time Kuwait-Berlin about 7 h
Intensive therapy in 12.000 meters altitude



CytoSorbents is Leading the Way To Prevent or Treat Life Threatening Inflammation


- CytoSorb® targets deadly inflammation in the ICU that leads to organ failure and death
- It is approved in the E.U. and is generating international revenue
- Untapped \$20B market opportunity and crucial unmet medical need
- Validation of the company and technology from many fronts
- Unique, highly profitable product and pipeline with little to no competition
- Experienced and responsible management team
- Potential major catalysts in the next 6-9 months
 - Revenue Growth
 - Strategic Partnerships
 - Clinical Data
 - Up-listing to National Market
 - New Product Development
 - Institutional Ownership

Q&A Session

CytoSorbents Corporation

OTCBB: CTSO

Phillip P. Chan, MD, PhD - CEO
7 Deer Park Drive, Suite K
Monmouth Junction, NJ 08852
pchan@cytosorbents.com



The Rise of An Emerging Critical Care Immunotherapy Company



CytoSorbents

Working to Save Lives Through Blood Purification